Occudo Quantitative Strategies LP Purchases Shares of 3,249 Amedisys, Inc. (NASDAQ:AMED)

Occudo Quantitative Strategies LP bought a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,249 shares of the health services provider's stock, valued at approximately $295,000.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in Amedisys by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock valued at $291,992,000 after acquiring an additional 10,817 shares during the last quarter. Pentwater Capital Management LP raised its stake in shares of Amedisys by 178.3% in the 4th quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider's stock valued at $107,132,000 after purchasing an additional 756,000 shares in the last quarter. Norges Bank bought a new position in shares of Amedisys during the fourth quarter worth about $83,061,000. Alpine Associates Management Inc. grew its stake in Amedisys by 3.2% in the fourth quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider's stock worth $80,632,000 after purchasing an additional 27,403 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new position in Amedisys in the fourth quarter worth about $72,970,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Stephens restated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Amedisys has a consensus rating of "Hold" and a consensus price target of $100.75.

Amedisys Stock Performance

NASDAQ AMED traded down $0.01 during trading hours on Thursday, reaching $93.59. The company's stock had a trading volume of 32,971 shares, compared to its average volume of 418,020. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The business has a 50-day simple moving average of $93.32 and a 200 day simple moving average of $91.64. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The stock has a market cap of $3.07 billion, a PE ratio of 37.14, a PEG ratio of 1.78 and a beta of 0.96.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business's revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.03 EPS. Equities research analysts predict that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.